Podcasts about Sun Pharma

In today's episode of The Daily Brief, we cover 2 major stories shaping the Indian economy and global markets:00:04   Intro00:45   Sun Pharma's big pivot11:57   India's oil sector results21:40   TidbitsWe also send out a crisp and short daily newsletter for The Daily Brief. Put your email here and we'll make you smart every day: https://thedailybriefing.substack.com/Note: This content is for informational purposes only. None of the stocks, brands, or products mentioned are recommendations or endorsements.

Welcome to Top of the Morning by Mint.. I'm Nelson John and here are today's top stories. 1. The Lodha Truce, ₹5,000 Cr Feud SettledAfter nine rounds of mediation and a mother's public plea, warring brothers Abhishek and Abhinandan Lodha have settled their ₹5,000-crore trademark dispute. As per the court-filed terms, Abhinandan can no longer use ‘Lodha' in isolation for real estate. Instead, he must use the full ‘House of Abhinandan Lodha' with clear disclaimers. Both parties waived financial claims and agreed to strict separation, including no shared employees or premises. Violations could trigger a ₹1 lakh/day penalty. Legal experts call it a rare, detailed resolution setting a precedent for intra-family brand disputes in India. 2. ITC's Record Profit Powered by Hotel DemergerITC reported a Q4 consolidated net profit of ₹19,807 crore, largely due to a one-time exceptional gain of ₹15,145 crore from the demerger of its hotel business. Adjusted net profit fell to ₹4,662 crore, down from ₹5,190 crore a year ago. Revenue rose 10% YoY to ₹20,376 crore, led by cigarettes and FMCG. EBITDA grew 3.7%, but margins slipped to 33.5%. A final dividend of ₹7.85 per share was announced, taking the full-year payout to ₹14.35. 3. Sun Pharma Profit Dips, But Margins Expand Sun Pharmaceutical Industries posted a 19% YoY decline in Q4 profit at ₹2,154 crore, even as revenue rose 8% to ₹12,959 crore. Strong domestic sales and global speciality drugs helped EBITDA grow 22% with margins expanding to 28.7%. US sales declined, but India sales grew 13.6%. The company declared a final dividend of ₹5.50 per share, taking FY25's total to ₹16. CMD Dilip Shanghvi highlighted promising global pipeline and recent acquisitions to strengthen the speciality segment. 4. Sensex Shake-Up: Trent, BEL In; Nestle, Indus Ind OutThe BSE Sensex is getting a facelift—Tata-owned Trent and defence PSU Bharat Electronics will replace Nestle India and IndusInd Bank from June 23. The reshuffle reflects shifting investor sentiment toward domestic consumption and defence stocks. Other key changes across indices: Dixon, Coforge, and Indus Towers will enter BSE 100; InterGlobe Aviation and Shriram Finance join the Sensex 50. IDFC First Bank replaces Canara Bank in the BSE Bankex. 5. De Beers Sees India's Diamond Market Doubling India's natural diamond market is set to double in five years, says De Beers Group CEO Al Cook, during his first visit to the country. India has overtaken China to become De Beers' second-largest market, after the US. De Beers is ramping up marketing spend, opening four new stores, and partnering with major players like Tanishq and GJEPC. While lab-grown diamonds (LGDs) are gaining ground, Cook emphasized their future lies in tech, not jewellery. De Beers has closed its LGD brand Lightbox amid a 90% fall in LGD prices. Learn more about your ad choices. Visit megaphone.fm/adchoices

Market Roars Back: Ceasefire & Tariff Pause Spark ₹16 Trillion RallyPeace on the borders and a tariff truce overseas gave Indian markets their best day in over four years. With India-Pakistan tensions cooling and US-China easing trade friction, the Nifty soared 3.8% and Sensex jumped 3.7%, adding ₹16 trillion to investor wealth. IT, banking, and blue-chip stocks led the charge, as FIIs and DIIs poured in over ₹2,600 crore. “We're in a sweet spot,” said Marcellus' Saurabh Mukherjea, flagging optimism ahead of earnings and a potential EM bull run in 2025. Trump's Drug Price Bombshell Rattles Indian Pharma Donald Trump's executive order to slash US prescription drug prices by 59% has stirred unease among Indian pharma exporters. Branded drugmakers like Sun Pharma, with up to 17% US revenue exposure, face risks if the rule is enforced. Generic manufacturers may escape unscathed—for now. With Trump pushing for price parity with Europe, and past efforts blocked in court, Indian pharma must brace for policy volatility in its top export market. Yes Bank's SMBC Deal Signals Fresh Start Yes Bank is readying for a reset with a ₹13,482 crore lifeline from Japan's SMBC, which will pick up a 20% stake. CEO Prashant Kumar called it a triple win: reducing SBI's stake overhang, onboarding a global strategic partner, and potentially securing a credit rating upgrade. With PE options ruled out and M&A off the table, the bank is betting on stability, not survival. Approval is expected by September, as analysts cautiously back the move. Worldline Looks to Exit India in $200M Deal French fintech Worldline is quietly preparing to exit India, hiring BNP Paribas to find a buyer for its B2B payments business. The move is part of CEO Pierre Vacheron's cost-cutting and portfolio-pruning turnaround plan following steep losses and multiple profit warnings. Razorpay and PayU are seen as front-runners. If it goes through, the deal could reshape India's digital payments battlefield—and help Worldline reset focus on core markets. Hero's Pivot Moment: Munjal Returns Amid EV PressureLeadership churn at Hero MotoCorp has brought 71-year-old Pawan Munjal back into the spotlight. With CEO Niranjan Gupta exiting and Honda closing in on sales, India's two-wheeler giant is in reset mode. Interim CEO Vikram Kasbekar steps in as the company struggles with slow EV adoption and a 4.5% YTD stock drop. With just 48,674 EV scooters sold versus TVS and Bajaj's 2 lakh+, Munjal's next move will be critical. Investors await Tuesday's earnings for clues on Hero's growth, margins, and roadmap.

In the latest episode of Inside Forbes India Podcast, Naini Thaker discusses her deep-dive profile on Dilip Shanghvi, the low-key founder of Sun Pharma, India's largest pharmaceutical company. Starting with just $200, Shanghvi's strategic focus on chronic therapies and high-value acquisitions—most notably Ranbaxy—helped shape Sun Pharma into a global force. The conversation explores how the company weathered challenges, such as price erosion, by doubling down on R&D and pivoting toward complex speciality drugs. It also highlights that Shanghvi's leadership is marked by humility, passion for his work, and a focus on patient care rather than wealth accumulation.

On this week's episode, Eric Schmidt, Sam Fazeli and Yaron Werber are joined by Biotechnology Innovation Organization's (BIO) John Crowley where they discuss biotech policy shifts, regulatory updates, obesity clinical trials and deal flow. The conversation begins with a focus on the obesity landscape including Novo Nordisk's CagriSema data, Roche's partnership with Zealand Pharma and Viking Therapeutics manufacturing agreements, signaling continued investment in the field. John Crowley then leads a conversation on policy and regulatory developments, sharing optimism about a more favorable U.S. policy environment for biotech. He highlights key priorities such as FDA modernization, PBM reforms and domestic manufacturing incentives. Crowley also notes bipartisan recognition of biotech as a strategic asset, though concerns persist around anti-science rhetoric, vaccine skepticism and regulatory challenges. Despite ongoing uncertainty, he sees more opportunities than threats for the industry. On the deal-making front, small-cap oncology acquisitions continue, with Sun Pharma acquiring Checkpoint Therapeutics and BMS consolidating its stake in 2seventy Bio. The discussion also covers biotech pipeline updates, including BioNTech's disappointing revenue guidance and Legend Bio's expansion of its CAR-T therapy manufacturing capacity. The episode concludes with insights into the broader biotech market, highlighting the impact of regulatory shifts, M&A activity and clinical trial data. While challenges remain, companies prioritizing innovation and execution continue to be well-positioned for long-term success. This episode aired on March 14, 2025.

It's Thursday, March 6th, 2025. This is Nelson John, let's get started.  ITC Hotels' Rough Debut January 29 was supposed to be a landmark day for ITC Hotels as it began trading independently. However, shares debuted nearly 30% below the implied price, dampening initial enthusiasm. Despite this, analysts remain bullish, valuing the company between ₹42,500-₹62,000 crore. ITC Hotels aims to expand to 200 hotels with 18,000 rooms in five years, relying on managed properties. However, investors worry about its limited owned-hotel pipeline. As competitors like IHCL and Marriott ramp up expansion, ITC Hotels must carve out its niche in a booming industry. Coforge's Record-Breaking Deal Coforge Ltd soared 8% after securing a record 13-year, $1.56 billion deal with US travel tech giant Sabre Corp. This long-term contract ensures strong revenue visibility for FY26, even as tech budgets shrink. Coforge also acquired Rythmos Inc. for $48.7 million and TMLabs for $12.5 million, further expanding its portfolio. A 1:5 stock split was announced to boost liquidity. However, Sabre's $5.1 billion debt raises cash collection concerns. Despite this, Coforge has outperformed peers, with its December order book reaching $1.4 billion—up 40% YoY. Tesla, Tariffs & Trump India's sky-high auto tariffs—up to 110%—have kept foreign automakers like Tesla out, despite Elon Musk's repeated attempts to enter the market. Now, US President Donald Trump has joined the fight, slamming India's “unfair” tariffs and threatening retaliatory action. As trade negotiations intensify, India has begun cutting duties on luxury vehicles—a possible opening for Tesla. With Trade Minister Piyush Goyal in the US for talks, the world watches to see if India will open its doors to global carmakers or protect its domestic industry. Cancer Drug Prices Set to Fall Cancer treatment in India is notoriously expensive, with some drugs costing up to ₹2 lakh per month. That's changing, thanks to domestic production under the government's PLI scheme. Leading pharma firms like Sun Pharma, Cipla, and Biocon are now manufacturing key cancer drugs, significantly cutting prices. For example, Trastuzumab, once ₹70,000 per month, now costs ₹12,000. More price reductions are expected as local production scales up. The initiative not only benefits Indian patients but also strengthens India's role as the “pharmacy of the world,” with exports to South America and Africa. Rupee Rises Amid Market Rally The rupee strengthened by 19 paise to close at 87.00 against the US dollar, supported by a rally in domestic equities, a weaker dollar, and falling crude oil prices. Volatility remained high, with the currency fluctuating between 86.93 and 87.20. Meanwhile, the dollar index slipped 0.79% amid Trump's escalating tariff moves. Brent crude also declined 0.75% to $70.51 per barrel. Markets responded positively, with the Sensex surging 740 points to 73,730 and the Nifty rising 255 points to 22,337. However, FII outflows and ongoing trade uncertainties could limit further rupee gains.

Apple's $500 Billion U.S. Investment Apple is making its largest financial commitment, pledging over $500 billion in the U.S. over four years to boost AI, silicon engineering, software, and R&D, creating 20,000 jobs. A key project is a Houston manufacturing facility assembling AI servers, set to open in 2026. Apple is also launching a Manufacturing Academy in Detroit to advance production techniques. This move follows Donald Trump's claim that Apple planned a major U.S. investment. With a supply chain spanning 24 silicon facilities across 12 states, Apple's investment solidifies its role in shaping American tech innovation. Mankind Pharma's Obesity Drug Bet Mankind Pharma is set to enter the $100 billion anti-obesity drug market, eyeing Semaglutide—the key ingredient in Ozempic and Wegovy—whose patent expires in 2026. It joins Dr. Reddy's, Natco Pharma, and Sun Pharma in the race to launch generic GLP-1 drugs. Given the complexity of development, Indian firms, including Mankind, will likely rely on third-party collaborations while leveraging strong branding. Mankind is expanding into chronic and specialty therapies, growing its chronic segment from 20.4% in FY15 to 35.5% in FY24. As competition intensifies, the company aims to carve out a space in the lucrative weight-loss segment. Infosys-Daimler AI Deal Extension Infosys is advancing discussions to extend and expand its $3 billion contract with Daimler, originally signed in 2020, adding AI tools to enhance IT services. The deal, covering network, security, SAP, and data centers, currently generates $400 million annually for Infosys. The extension, from 2028 to 2029, aligns with Infosys CEO Salil Parekh's strategy of securing high-value, AI-driven contracts. The company's manufacturing sector revenue has surged from $1.3 billion in FY20 to $2.8 billion in FY24. With businesses prioritizing AI, Infosys's early renewal signals a broader shift toward AI-powered IT services. NTPC-EDF Green Energy Partnership State-run NTPC Ltd and EDF India, a subsidiary of France's EDF, have signed a non-binding agreement for a 50:50 joint venture in pumped storage, hydro, and renewable projects across India and neighboring countries. NTPC, India's largest power producer, is targeting 60GW renewable capacity by 2032. The company recently listed NTPC Green Energy Ltd (NGEL) to accelerate green hydrogen, methanol, and SAF investments. In January, PM Narendra Modi laid the foundation for India's first green hydrogen hub in Andhra Pradesh, part of a ₹1.85 trillion investment plan under the National Green Hydrogen Mission. RBI Eases Withdrawal Limits for New India Cooperative Bank The RBI has allowed depositors of New India Cooperative Bank to withdraw up to ₹25,000 per account after dissolving its board over supervisory concerns. More than 50% of depositors can now withdraw their full balances, while others can access up to ₹25,000 via branches and ATMs from February 27, 2025. The bank held ₹2,436.4 crore in deposits as of March 2024, with a declining loan book and capital adequacy ratio (9.1%) below the required 10% for two years. RBI assured depositors it is closely monitoring the situation and taking necessary measures.

Today's guest is Vickram Srivastava, Head of North American Supply Chain at SUN Pharma. SUN Pharma is a global pharmaceutical corporation based in Mumbai, India. The company produces and distributes pharmaceutical formulations and active pharmaceutical ingredients (APIs) to over 100 countries worldwide. Vickram joins us on today's program to share his expertise on the critical challenges facing the sector, particularly in the wake of global disruptions and increasing regulatory demands. This episode is sponsored by Arkestro. Learn how brands work with Emerj and other Emerj Media options at emerj.com/ad1.

Join moderator Emily Wallack as we hear how Mark, a patient living with moderate-to-severe plaque psoriasis, rediscovered self-love after finding ILUMYA® (tildrakizumab-asmn), a treatment that he receives for little to no cost with coverage under Medicare Part B with a supplement. Dermatologist Dr. Omar Noor also joins to offer insights on diagnosing and treating psoriasis. This episode is sponsored by Sun Pharma. To view important safety information: ilumya.com   

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — Ascendis, Novo ink partnership The bad — Court blocks Sun Pharma launch The ugly — FDA moves to delist phenylephrine

Welcome to CNBC-TV18's Marketbuzz Podcast. Here are top developments from around the world ahead of the trading session of November 4 -Recap: It has been a volatile last two weeks for the Nifty, having ended October on a negative note. The month saw the index fall 6%, marking its worst monthly drop since March 2020. -Samvat 2081 has begun on a positive note with the index ending higher during the token one-hour Mahurat Trading session on Friday. The start of November also is no-less packed with action as the Indian market participants will have eyes on all four corners of the world due to various cues emerging during the week. -The all important US Presidential Election outcome will be known this week, as will be the US Fed interest rate decision. Consensus still remains that the FOMC will slash rates by 25 basis points. Meanwhile, manufacturing activity in the US fell to the lowest level since July 2023. -Back home, earnings season continues with multiple broader market companies, and big ones at that, reporting results in the upcoming week. Among the Nifty names, stocks like Dr. Reddy's, Titan, Tata Motors and India's largest lender State Bank of India, along with the newest index entrant, Trent, will be reporting results this week. -Samir Arora of Helios Capital during the Mahurat Trading session spoke about the fact that the next six to nine months, it will be good to look at growth companies but auto and consumer stocks may not do well. Market veteran Ramesh Damani also highlighted two themes that he would want to focus on for the next Samvat, which were Digital Public Infrastructure and Pharma. -This morning the GIFT Nifty was lower, trading at a discount of more than 80 points to Nifty Futures Friday close, indicating a gap-down start for the Indian market. -Stocks to watch: NCC, Ashoka Buildcon, MOIL, NBCC, NMDC, Premier Energies, Zen Technologies, Sun Pharma, Apollo Hospitals -Shares rose in Asia, with those in Hong Kong and mainland China higher in early trade. US stock futures were steady after Wall Street's gains Friday following robust earnings from the likes of Amazon.com and Intel Corp. Japanese markets are closed for a holiday, which means there will be no Treasuries trading in Asian hours. -In commodities, Oil advanced after OPEC+ agreed to push back its December production increase by one month and tensions escalated again in the Middle East. Brent rose as much as 2% to more than $74 a barrel. Gold was stable after retreating from a record high last week Tune in to Marketbuzz Podcast for more cues 

In 2025 key changes impact Medicare beneficiaries. Listen as Jason Harris, NPF VP of Government Relations & Advocacy and dermatologist/rheumatologist Dr. Alice Gottlieb with the Dept. of Dermatology, Icahn School of Medicine at Mount Sinai, discuss issues and tips for transitioning to Medicare health coverage, the $2,000 expense cap, and smoothing expenses. This episode is made possible with support from Sun Pharma and Novartis. 

Audio roundup of selected biopharma industry content from Scrip over the business week ended 9 August 2024. In this episode: Amgen positions for obesity and diabetes; BMS returns TIGIT asset in pipeline reshuffle; is Kerendia the next jewel in Bayer's crown?; Japan pharma firms cut jobs; and Sun Pharma seeks GLP-1 partner. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

In this episode of Market Minutes, Lovisha Darad talks about key events that investors will eye on August 1. After the US Federal Reserve hinted at interest rate cut from September, can it enthuse Indian equity markets? Additionally, market observers will keenly watch out how the India Inc's Q1 earnings pan out – Tata Motors, Sun Pharma, Adani Ports will deliver results today. Apart from that, Ceigall India IPO will open for subscription, while Akums Drugs IPO is set to close. Also, catch VK Vijayakumar of Geojit Financial Services on Voice of the Day segment. Market Minutes is a morning podcast that puts the spotlight on hot stocks, key data points, and developing trends.

-Welcome to CNBC-TV18's Marketbuzz Podcast. Here are the top developments from around the world ahead of the trading session of August 1  -It's yet another day of waiting for the Nifty to cross 25,000. Nifty and 25,000 are now separated by 49 points. It still seems a long way away considering the index came within 0.2 points of that on Monday, 30 points on Tuesday and 16 points on Wednesday but could not cross that landmark. 24,984 was the high made by the Nifty on Wednesday and that now becomes the first hurdle to cross on Thursday for the Nifty. -Global cues are important today as the US Federal Reserve has kept interest rates unchanged but Chair Jerome Powell said that a rate cut in September is "on the table" provided that data continues to be as encouraging as it currently is.  -Wall Street cheered the Fed commentary with the S&P 500 marking its best day since February this year, while the Nasdaq ended with gains of over 2%. -This morning in Asia, equities and US futures were broadly higher on firming signs that the Federal Reserve will soon cut interest rates. Japanese stocks fell to reflect a stronger yen. Equities in Australia and South Korea rose alongside Hong Kong share futures. Contracts for the S&P 500 and the Nasdaq 100 both climbed to compound Wednesday's advances ignited by a tech rally.  -In terms of commodities, oil prices rose in early Asian trading, extending strong gains in the previous session after the killing of a Hamas leader in Iran raised the threat of a wider Middle East conflict and on signs of strong oil demand in the U.S. Global benchmark Brent crude futures rose 0.8%, to $81.51 per barrel this morning.  -Back home, Nifty ended the month of July with gains of 3.9%, following up a 6.6% advance in June. August generally has been a positive month for the Nifty as it has delivered positive returns in three out of the last four years. Last year saw the index fall 2.5%, but gained 3.5% in 2022, 8.7% in 2021 and 2.8% in 2020.  -The first day of the new month will also be the weekly options expiry of the Nifty 50 contracts. -Stock to track: Infosys, Coal India, Tata Steel, Bank of Baroda, Prestige Estates, Phoenix Mills, Relaxo Footwear  -Earnings: Adani Enterprises, Adani Ports, Sun Pharma, ITC, Tata Motors, Dabur, Kalyan Jewellers, Thermax, Tube Investments, HPL Electric and Power, and Godrej Agrovet  -The Gift Nifty was trading 0.02% ahead of the Nifty futures' Wednesday close, implying a flat start for the market today.   Tune in to the Marketbuzz Podcast for more cues 

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — FDA approves Sun Pharma hair loss drug  The bad — FDA issues harsh warning letter to Indian CDMO Brassica  The ugly — EMA issues negative opinion on Eisai-Biogen Alzheimer's drug 

Use AI to Speed up Your Work Flow Ethically and Securely. There are lots of courses on AI out there, but this one is specific only to medical writing and editing.  Access the AIMWE course waitlist. https://www.learnamastyle.com/waitlist/ Leqselvi for Alopecia Areata: The FDA has approved deuruxolitinib (Leqselvi) as a first-line treatment for adults with moderate to severe alopecia areata (AA). Developed by Sun Pharma, this oral selective inhibitor of Janus kinases JAK1 and JAK2 is typically dosed at 8 mg twice daily. The approval, based on the THRIVE-AA1 and THRIVE-AA2 trials, marks an important addition to limited treatment options for AA, which has significant psychological impacts. Femlyv Dissolvable Birth Control: The FDA has approved norethindrone acetate and ethinyl estradiol (Femlyv) as an oral dissolvable birth control pill, expanding access for those who have difficulty swallowing. This form of hormonal birth control, in use since 1968 as a swallowable tablet, also helps manage conditions like endometriosis and PMDD. The approval, based on a study of 743 women, offers a new option with common side effects like headache and nausea. Brineura for Batten Disease: The FDA has expanded the indication for cerliponase alfa (Brineura) to treat neuronal ceroid lipofuscinosis type 2 (CLN2 disease) in children under 3 years of age. Developed by BioMarin Pharmaceutical, this enzyme replacement therapy, initially approved in 2017, is administered by infusion into the brain. The expanded approval was based on a phase 2 trial showing reduced motor function decline and delayed disease onset. Erzofri for Schizophrenia: The FDA has approved paliperidone palmitate (Erzofri) extended-release injectable suspension for treating schizophrenia and schizoaffective disorder in adults. This long-acting injectable (LAI) antipsychotic, administered once a month, improves patient adherence by reducing dosing frequency. Developed by Luye Pharma Group, it was granted a U.S. patent in 2023 and approved under the 505(b)(2) pathway. Eque-cel for MS: The FDA has approved the IND application for equecabtagene autoleucel (Eque-cel) for treating multiple sclerosis (MS). Developed by IASO Biotechnology, this chimeric antigen receptor autologous T cell injection showed promising efficacy in six autoimmune diseases in a Chinese trial. MS, affecting 3.07 million people worldwide, is characterized by CNS demyelination and neuronal injury, with Eque-cel offering a new treatment option. Spravato for TRD: Johnson & Johnson has submitted an sNDA for esketamine (Spravato) as a monotherapy for adults with treatment-resistant depression (TRD). Already approved in combination with an oral antidepressant, esketamine is an NMDA receptor antagonist that rapidly alleviates depressive symptoms. The submission is based on Phase 4 TRD4005 study results, showing rapid improvement in depression scores with a consistent safety profile. ZW191 Anti-Tumor Agent: The FDA has cleared the IND application for ZW191, a novel antibody-drug conjugate (ADC) targeting folate receptor alpha (FR⍺) in cancers like gynecologic and NSCLC. Developed by Zymeworks, this TOPO1i ADC uses a novel payload, ZD06519, showing robust antitumor activity and a tolerable safety profile in preclinical models. Clinical development of ZW191 is planned to begin in the second half of 2024.

Marketbuzz Podcast: Indian markets may see a gap-up start according to the GIFT Nifty. Watch out for stocks like HDFC Bank, Avenue Supermarts, Sun Pharma.

-Welcome back to CNBC-TV18's Marketbuzz Podcast. Here are all the important updates ahead of the trading session of June 24 -On Friday, frontline indices consolidated higher whereas the sectoral rotation continued with banks doing well last week. Bank Nifty ended 3.5% higher. The Nifty, meanwhile, huffed and puffed but managed to eke out some weekly gains. -Monsoon progress is also very critical as June has seen poor rains across the country. Meanwhile, India is to be included in the GBI-EM Global Diversified Index from June 28. Also, bond markets could see inflows of $30 billion over the next 10 months. -The upcoming week will be the June F&O series expiry and it has already been a 1,000-point series for the Nifty on the upside. While it will aim to end the week and the series on a high, the question is, will it get the required support from banks and IT stocks that lent support to the index for most of last week? -As of this morning, GIFT Nifty was trading with a discount of nearly 40 points from Nifty Futures' Friday close, indicating a start in the red for the Indian market today. -While the Nifty remains in consolidation mode, the action will lie in specific stocks, as has been the trend in the last few trading sessions. Most of the GST-linked names from fertilisers, to road construction companies to even gaming firm Delta Corp, may see a reaction during Monday's trading sessions. Block deals also continue with CarTrade Tech likely to see one go through on Monday. -The focus is starting to move towards Budget expectations. In fact, with preps underway several reports are hinting at a potential windfall for the middle class. According to a CNBC Aawaz report, the government is preparing to provide some relief to the middle class in this year's Budget. Stocks to watch: GST-linked names, CarTrade, banks, IT, Vedanta, Cipla, Sun Pharma, Lupin, MCX, Prestige Estates, PB Fintech, JSW Energy -Asian shares edged lower this morning, kicking off a week that includes measures of inflation that will help guide bets on the outlook for global interest rates. An index for the region's stocks was set to slip for a third session on Monday, with equities in South Korea falling and those for Japan swinging between gains and losses. Contracts for Hong Kong shares pointed to declines while US equity futures were steady after the S&P 500 fell on Friday amid a large options expiry. -This week, while parsing inflation data, traders will also be keeping watch on rising political risks. The first UK prime ministerial and US presidential debates are scheduled and the first round of voting in the French legislative election is set to take place this coming weekend. -In commodities, oil extended Friday's decline toward $80 a barrel amid a stronger greenback and a technical indicator suggesting the recent rally has gone too far. Gold fell amid a re-think of the Fed's rate cut outlook. Tuned in to Marketbuzz Podcast for more news and cues

Welcome back to CNBC-TV18's Marketbuzz Podcast. Here are all the important updates ahead of the trading session of June 20 -The bulls seem to have taken a breather. It turned out to be another day and another record for the Nifty 50 but the index could not sustain at those levels. 23,664 is now the new record high for the Nifty. The index fell 150 points from those levels and ended with losses, snapping a four-day winning streak. -Big focus seems to be on banks. The Nifty bank has hit an all time high almost at 52000.  HDFC bank is now up almost 15% in June. Led by the underperforming HDFC Bank, six out of the top seven Nifty contributors are banking stocks, which also kept a lid on the Nifty downside. In fact, HDFC Bank and ICICI Bank together contributed nearly 120 points to the Nifty's gains. -HDFC Securities says although the Nifty is at highs, there is no confirmation of any reversal pattern building up on the charts at higher levels. The analyst only sees further weakness in the index if it slips below the 23,300 mark. This setup may be negated if the Nifty moves further higher. -Asian shares retreated this morning following a rally in the previous session as investors sought new catalysts after a holiday in the US. The MSCI Asia Pacific Index slipped 0.1% after jumping 1% on Wednesday, with shares in Japan and Australia posting small losses. Futures for Hong Kong indicated declines. The pan-European Stoxx 600 slipped 0.2% after two days of gains. - In the UK, inflation has fallen to 2% in May with services inflation still elevated. The Bank of England is likely to leave rates unchanged in today's meeting. In the US, jobless claims and housing starts data will be in focus today. US markets, meanwhile, were closed on Wednesday for a holiday. -On the commodities front, oil remains above $85 on geopolitical concerns. -GIFT Nifty was trading higher at a premium of nearly 20 pts from Nifty Futures Wednesday close, indicating a flat-to-positive start for the Indian market. -Stocks to watch: MAS Financial Services, PNB Housing, Sun Pharma, Sapphire Foods, GMR Urban, Reliance Industries, Vodafone Idea, Bharti Airtel, Som Distilleries, Godrej Group stocks Tune in to the Marketbuzz Podcast for more cues

In this episode of Market Minutes, Sucheta Anchaliya talks about all the important factors to watch. Today's developments: Sun pharma acquisition, Nvidia overtakes Apple market capitalisation to current market setup. Also catch Soni Patnaik, Assistant VP- Derivative research at JM financial in the Voice of the Day segment. Market Minutes is a morning podcast that puts the spotlight on hot stocks, keys data points and developing trends.

This is the Catch Up on 3 Things for the Indian Express and I'm Flora Swain.It's the 23rd of May and here are today's headlines.Tensions flared in Nandigram in West Bengal's Purba Medinipur district today. Hours after a woman worker of the BJP was killed and seven others were injured after being attacked on Wednesday night, days before the sixth phase of the Lok Sabha elections in the state. As the BJP took to the streets in protest today by torching shops and blocking roads using trees and setting them on fire, security was beefed up with Rapid Action Force and central forces being deployed, apart from the police.A senior Kolkata police officer said that the initial probe into the “murder” of Bangladesh MP Anwarul Azim Anar revealed that one of his friends had paid around Rs 5 crore to kill the neighbouring country's parliamentarian. Anar, who went missing in Kolkata since 13th of May, was found murdered and three people have been arrested, Bangladesh Home Minister Asaduzzaman Khan had said on Wednesday. The West Bengal Police had said investigation of the case has been taken up by the state CID.Recent heavy showers have caused significant destruction in Kerala, and resulted in at least four deaths. The India Meteorological Department has issued an orange alert for Ernakulam, Thrissur, Idukki, Palakkad, Malappuram, Kozhikode, and Wayanad districts today. With heavy rainfall forecast, the weather department has also issued a yellow alert for Thiruvananthapuram, Kollam, Alappuzha, Pathanamthitta, Kottayam, Kannur and Kasargod districts. An ‘orange' alert is an indication to be prepared and warns of waterlogging and major traffic disruptions.Frontline equity index NSE Nifty 50 hit an all-time high of 22,880.55, going past the previous mark of 22,794.  30-share BSE Sensex, along similar lines, is trading 873.12 points, or 1.19 per cent higher, at 75,061.74 points.Among the Sensex firms, Asian Paints, Axis Bank, State Bank of India, Larsen & Toubro, Reliance Industries, Wipro, Titan and Bharti Airtel were the major gainers. On the other hand, Sun Pharma, JSW Steel, Power Grid, and Tata Steel were the laggards.Norway said it will further tighten its restrictions on the entry of people from Russia. It further stated that those with tourist visas issued by Norway before regulations were tightened in 2022 or issued by another European country will be barred from entering the Scandinavian country as of next week. Justice Minister Emilie Enger Mehl said the tightening was a response to “Russia's illegal war of aggression against Ukraine.” Norway has a 198-kilometer (123-mile) -long border with Russia in the Arctic.This was the Catch-Up on the 3 Things by The Indian Express.

Welcome to CNBC-TV18's Marketbuzz Podcast. Here are all the important cues ahead of the trading session of May 22 - Traders in India's stock markets saw a rangebound session" for the Nifty. The index found support at the lower end of the trading range at 22,400 and resistance at the upper end of the range at 22,600, eventually eking out modest gains to sustain above the 22,500 mark. -This morning, GIFT Nifty was trading with a premium of more than 15 points from Nifty Futures' Tuesday close, indicating a flat-to-positive start for the Indian market. -For the mid-week trading session on Wednesday, stocks like BHEL, Metropolis, JK Tyre, VA Tech Wabag, Gulf Oil Lubricants will react to their results that were reported after market hours on Tuesday. -Wednesday's session will also see Nifty names like Sun Pharma and Grasim report results along with broader market names like Nykaa, Petronet LNG, Jubilant Foodworks, Metro Brands, Gland Pharma, Ramco Cements, Garden Reach Shipbuilders, among other prominent names. -Globally, Nvidia is the talk of the town at AI events leading into this week's earnings.T his week, Microsoft, which provides servers to OpenAI, will announce new AI advancements and features that were developed on the company's massive clusters of Nvidia GPUs. The company is hosting its Build conference in Redmond, Washington. -Overnight in the US, all three indexes closed in positive territory, with the S&P 500 and the Nasdaq Composite closing at new records as investors looked toward AI darling Nvidia's earnings report. The Nasdaq Composite rose 0.22% to 16,832.62. The S&P 500 added 0.25% to 5,321.41. The Dow Jones Industrial Average closed 0.17% higher at 39,872.99. -Asian stocks struggled for solid footing amid a lack of local drivers after the S&P 500 crept to another record ahead of results from giant chipmaker Nvidia Corp. Shares in Japan fell as the country reported a trade deficit, while those in Australia climbed. Equity benchmarks in Hong Kong and mainland China slipped at the open. MSCI Inc.'s Asia Pacific index is down for a second day after a seven-session win streak. -Stocks to watch: BHEL, Metropolis, JK Tyre, VA Tech Wabag, Gulf Oil Lubricants -Results: Sun Pharma, Grasim report, Nykaa, Petronet LNG, Jubilant Foodworks, Metro Brands, Gland Pharma, Ramco Cements, Garden Reach Shipbuilders Tune in to Marketbuzz Podcast for more cues

Welcome to Top of the Morning by Mint, your weekday newscast that brings you five major stories from the world of business. It's Thursday, April 25, 2024. My name is Nelson John. Let's get started: The Indian equity markets increased marginally on Wednesday. Benchmark indices Sensex and Nifty both rose by about 0.15 per cent. Vodafone Idea, Tata Consumer, and Sun Pharma were some of the notable names that lost a lot of shareholder value during yesterday's trading session. The board of Tata Sons is soon headed for a revamp, with two directors set to retire over the next 15 months, reports Varun Sood. Last month, a new independent member joined. In effect, about one-third of the Tata Sons 10-member board will be going through a turnover in just over a year. The main task for the new board members will be to ensure that the Tata group becomes a debt-free company. The group currently owes over 20,000 crore rupees to its lenders. But through selling of shares in its crown jewel TCS, and other measures, Tata Sons can realistically achieve this goal by next year.  Kotak Mahindra Bank received a huge jolt yesterday when the banking regulator barred it from onboarding any new customers online. The Reserve Bank of India also barred Kotak Mahindra from issuing any fresh credit cards. RBI said that serious lapses in the bank's IT services had forced it to take such a drastic measure. Shayan Ghosh writes that existing Kotak customers shouldn't face any hurdles, but this is a huge loss of confidence for new CEO Ashok Vaswani's bank. At Mint, we've been steadily bringing you some in-depth election coverage. For today's Long Story, we invited Ruhi Tewari to write about the election landscape in Uttar Pradesh. UP is inarguably the most pivotal state when it comes to the general election: 15% of all elected Lok Sabha members come from this state. But what issues are UP citizens voting on? The usual, writes Ruhi: electricity, roads, and water. India's most populous state will vote for the party that guarantees them these basic necessities. However, the ruling BJP is expected to win this state again—not because of the Ram temple, but because of an improved law-and-order situation in the state. Ruhi gets the on-ground pulse from Lucknow, Ayodhya, and Mathura for this deftly reported story. If you've watched IPL this year, a host of betting apps would've tried to lure you in. But if you log in, they don't just offer bets on how much Dhoni will score or how many runs RCB will lose by this time—you can even punt on the results of the general election. Varuni Khosla writes that the advertising standards council of India has flagged brazen promotions by these illegal betting apps, but to no avail. This issue assumes importance especially as the Supreme Court forced Patanjali to apologise for its misleading advertisements, and hauled up other consumer goods companies as well. If you've seen any betting apps on a website, chances are you have searched for some betting sites yourself. This is called a targeted ad: catering to specific users' needs, based on their search or browsing history. If you're surprised, I agree: it's quite invasive. To help with that, the ministry of corporate affairs has initiated the Digital Competition Bill. This bill is only likely to be taken up after the national election is concluded, but will help with maintaining your privacy online, reports Gireesh Chandra Prasad. However, executives from the adtech industry have said this will result in fewer monetising avenues. In this battle for privacy versus revenue, who will win? We'll only find out by the end of the year—that's when the bill is likely to be introduced in Parliament. We'd love to hear your feedback on this podcast. Let us know by writing to us at feedback@livemint.com. You may send us feedback, tips or anything that you feel we should be covering from your vantage point in the world of business and finance. Show notes:New faces on Tata Sons board? Bhaskar Bhat, Ralph Speth near retirement RBI bars Kotak Mahindra Bank from adding new customers via web, mobile appWork is worship: Bijli, sadak, paani are once again the key poll issues in UPIPL, elections are all fair game on illegal betting appsTargeted ads become focal point of digital competition debate

Marketbuzz Podcast: The GIFT Nifty is indicating a gap down start for the Indian markets. Watch out for stocks like Vodafone Idea, Bharti Hexacom and Sun Pharma.

Synopsis: In this episode of Biotech2050, Scott Megaffin, CEO of Adiso Therapeutics, shares valuable insights on the challenges and opportunities in the biotech industry. His deep involvement in the pharmaceutical and biopharmaceutical sector has shaped his strategic approach to leadership and business management. Scott emphasizes the importance of a CEO's versatility and willingness to undertake any task, no matter how small, and also highlights the burden of proving the value of differentiation in a small company. The conversation delves into the significance of collaboration with research institutions and strategic partners, underlining the importance of differentiation and collaboration in competitive markets. Scott's reflections on his career journey and the development of Adiso's asset Adso 51 provide valuable lessons for professionals and entrepreneurs in the field, making this episode a must-listen for biotech entrepreneurs and professionals seeking to enhance their ability to differentiate and collaborate in competitive markets. Biography: Scott joined Adiso Therapeutics as Chief Executive Officer in January 2022, bringing more than 35 years of successful industry leadership, having held multiple senior executive, CEO and board director roles during his career at both Fortune 500 pharmaceutical and emerging biotechnology companies. Among Mr. Megaffin's many career leadership roles, he previously served as the CEO of Adastra Pharmaceuticals Inc., a pioneer in the pursuit of better treatment options for high unmet need cancers, where he led the company from early informative to clinical-stage advancement of first-in-class clinical programs, and ultimately to its acquisition by Cothera Bioscience. Earlier, he served as a President of Churchill Pharmaceuticals, Inc., leading the organizational growth and development of a fully differentiated oral oncology asset for metastatic castrate resistant prostate cancer through FDA approval and ultimately a transaction to Sun Pharma. Mr. Megaffin has held numerous global strategic and operational positions of increasing responsibility within Onconova, Schering-Plough, Yamanouchi, Pharmacia, and Bristol-Myers Squibb. During his career Scott has led six global drug development programs resulting in regulatory approvals. He possesses far reaching knowledge in a broad number of therapeutic categories including oncology, anti-infectives, inflammation, pain, critical care, and virology. Mr. Megaffin currently serves as a board member of Adastra and on the Board of Directors for BioNJ, the biotechnology and life science organization of New Jersey. Mr. Megaffin holds a B.S. in Biology from Pittsburg State University.

Indian benchmark indices, Sensex and Nifty 50, are likely to open in the red in the trading session of January 31, a day ahead of the Budget 2024 speech by Union Finance Minister Nirmala Sitharaman. Overnight cues are quite mixed. The US market ended mixed with the NASDAQ bearing the brunt of selling pressure in Alphabet and Microsoft following earnings. Asian shares fell broadly in morning trade as Chinese markets wobbled after an official factory survey showed China's manufacturing activity in January contracted for a fourth straight month. Meanwhile, GIFT Nifty indicated a start in the red for the domestic market. The index was trading 0.20% lower at 21,627 at 8:38 am, lower than Nifty 50's close of 21,522.10 in the previous session. Key stocks to track: Maruti Suzuki, L&T, Dr Reddy's, Ambuja Cement, Shree Cement, Sun Pharma and more Tune in to Marketbuzz Podcast for more cues

In this episode of Market Minutes, Harshita talks about the key factors to watch out for today before domestic equity market open.The Sensex and Nifty are expected to see weakness in near-term and analysts advise stock-specific approach. Yes Bank, Shyam Metalics, Sun Pharma and LIC among the stocks in in focus on January 3. Supreme Court to pronounce judgment on a batch of petitions seeking investigation into Hindenburg allegations on Adani Group. Globally, US stocks tumbled overnights, while Asia-Pacific markets tracked Wall Street losses to trade lower today. Catch the global market set up, and also hear from Jigar Trivedi from Reliance Securities in the Voice of the Day segment. Market Minutes is a morning podcast that puts the spotlight on hot stocks, key data points, and developing trends.

Indian benchmark indices, Sensex and Nifty 50, are likely headed for a flat opening on December 19, as the global rally triggered by hopes of US interest rate cuts in 2024 has slowed down. India's GIFT Nifty was down 0.04% from its overnight close at 21,478 as of 8:09 am IST, indicating the Nifty 50 is likely to open around its December 18 close of 21,418.65. The Nifty and Sensex declined in the previous session after rallying to record highs for most of this month. So far in December, the Nifty has risen 6.38% and is on course for its best month since July 2022. Meanwhile, in the overnight session, Wall Street equities closed marginally higher. In morning trade, Asian shares steadied as traders' focus turned on Japan's central bank and whether it might edge further away from its ultra-easy monetary policy. Oil prices rose for a second session, as attacks by Yemen's Iran-aligned Houthi militants on ships in the Red Sea disrupted maritime trade. Stocks to watch: Vedanta, Sun Pharma, PSU Banks, OMCs, Devyani International, PNC Infra, Kaynes Tech and more Tune in to the Marketbuzz Podcast for more cues

Equity Cash: Sansera, IOL Chem and Oil India Equity Derivatives: Lalpathlabs 2600 CE, Sun Pharma 1260 CE Index Derivatives: Nifty 21400 CE, Nifty Bank 47800 CE --- Send in a voice message: https://podcasters.spotify.com/pod/show/kunvarji-group1/message

India's benchmark indices, Sensex and Nifty 50, are set to open higher on December 12, tracking the rise in Asian peers ahead of a crucial inflation data and the US Federal Reserve policy decision. India's GIFT Nifty was little changed from its overnight close at 21,140.50, as of 8:05 a.m. IST, indicating that the Nifty 50 will open higher than its Monday closing of 20,997.10. Globally, all three major Wall Street indexes posted their new 2023 closing highs in the overnight session, ahead of key economic data and Fed monetary policy decision. Asian markets rose in morning trade. Stocks to watch: Dixon Technologies, SpiceJet, Mankind Pharma, Infosys, Sun Pharma Tune in to the Marketbuzz Podcast for more

In this episode of Meeting Mic, we bring you Healio's top headlines from ACG 2023. Paul Feuerstadt, MD, FACG, AGAF, discusses data that link health-related quality of life and microbiome composition among patients with recurrent Clostridioides difficile infection. :38 Edward V. Loftus Jr., MD, FACG, discusses results from the INSPIRE trial for ulcerative colitis. 7:52 Jan Wehkamp, MD, PhD, discusses results from the QUASAR study, in which Tremfya outperformed placebo in clinical response patients with ulcerative colitis. 12:08 Paul Feuerstadt also discusses the evolution of treatment for Clostridioides difficile infection, from antimicrobials to recently FDA-approved live biotherapeutics. 15:32 Thomas F. Imperiale, MD, discusses the results of the BLUE-C study, which evaluated the clinical performance of Cologuard, a next-generation, multitarget stool DNA test. 21:08 Read the full coverage here: https://www.healio.com/news/gastroenterology/20231023/video-rebyota-not-only-shuts-down-recurrence-also-affects-quality-of-life-in-c-diff https://www.healio.com/news/gastroenterology/20231025/video-risankizumab-a-great-option-for-patients-induces-clinical-remission-in-uc https://www.healio.com/news/gastroenterology/20231024/video-more-than-75-of-uc-patients-achieve-clinical-response-at-24-weeks-with-tremfya https://www.healio.com/news/gastroenterology/20231025/video-future-is-now-here-for-recurrent-c-difficile-thanks-to-live-biotherapeutics https://www.healio.com/news/gastroenterology/20231025/sensitivity-of-nextgeneration-cologuard-in-precancer-detection-numerically-exceeded-fit Disclosures: Feuerstadt reports financial relationships with Ferring Pharmaceuticals, Regeneron Pharmaceuticals, Seres Therapeutics and Takeda Pharmaceuticals. Imperiale reports grant and research support from Exact Sciences. Loftus reports financial relationships with AbbVie, Alvotech, Amgen, Arena, Avalo Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Exact Sciences, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Scopes, Janssen, KSL Diagnostics, Lilly, Morphic, Ono Pharma, Pfizer, Protagonist, Receptos, Robarts Clinical Trials, Scipher Medicine, Sun Pharma, Surrozen, Takeda, Theravance and UCB. Wehkamp reports no relevant financial disclosures.

In this episode of Market Minutes, Sucheta Anchaliya talks about all the important factors to watch today developments: Sun Pharma acquisition, Valiant Laboratories listing, BHEL and Lupin to global market setup. Also catch Rajesh Kumar Jain of Anand Rathi Group in the Voice of the Day segment. Market Minutes is a morning podcast that puts the spotlight on hot stocks, keys data points and developing trends

Hear Todd's journey to finding skin clearance with the help of ILUMYA® (tildrakizumab-asmn) for his moderate-to-severe plaque psoriasis. Victor Czerkasij, a nurse practitioner with over 20 years of experience treating patients with psoriatic disease, joins to offer insights on diagnosing, treating, and managing psoriasis. This episode is sponsored by Sun Pharma. Important safety information: https://bit.ly/2We7fIS .

Thanks for your interest in this podcast. Please read this important program information before listening. Access to the post-test and to claim credit for participating is included below.Activity OverviewThis PER® Spectives™ podcast features a discussion among 3 optometrists on challenges and unmet needs associated with traditional treatments for meibomian gland dysfunction (MGD)-related dry eye disease (DED) — and opportunities for MGD treatment that may come with new and emerging topical therapies. In addition, the panel discusses myths and misconceptions that may affect outcomes in patients with MGD-DED. This program is designed to help clinicians better appreciate the impact ofMGD-DED on patients and optimize the growing toolkit of available therapies.Accreditation/Credit DesignationPhysicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 0.25 AMAPRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Acknowledgment of Educational Grant SupportThis activity is supported by an educational grant from Bausch + Lomb.Target Audience This educational activity will be targeted to practitioners who are involved in treating patients with MGD, such as Optometrists, Ophthalmologists, NPs, PAs, and nurses.Learning ObjectivesUpon successful completion of this activity, you should be better prepared to: • Analyze key trial data and real-world evidence surrounding current treatments for MGD-associatedDED• Evaluate key clinical trial data for emerging agents being studied for the potential treatment of MGD-associated DEDFaculty:Mile Brujic, OD, FAAOPartnerPremier Vision GroupBowling Green, OHDisclosures: Advisory/Research Support: ABB Optical, Alcon Laboratories, Allergan, Art Optical, Bausch +Lomb Health, Contamac, CooperVision, CSEye, Horizon Therapeutics, Johnson & Johnson Vision Care,Kala, Novartis, Optovue, Oyster Point, RVL, Sun Pharma, Tarsus, Tangible Science, Santen, WalmanOptical, ZeaVisionDavid Kading, OD, FAAO, FCLSADisclosuresWalter Whitley, OD, MBA, FAAODirector of Professional Relations and EducationRegional Medical Director - Mid-AtlanticEyeCare Partners, LLCDisclosures: Consultant: Alcon, Allergan, Bausch + Lomb, Bruder, I-MED Pharma USA, KalaPharmaceuticals, Novartis, Oyster Point Pharma, Regener-Eyes, Santen Pharmaceutical, ScienceBasedHealth, Sun Pharma, Tarsus Pharmaceuticals, Théa Pharma; Speakers' Bureau: Alcon, Allergan, Bausch +Lomb, Kala Pharmaceuticals, Novartis, Oyster Point Pharma, Santen Pharmaceutical, ScienceBasedHealth, Sun Pharma.The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.Off-Label Disclosure and DisclaimerThis activity may or may not discuss investigational, unapproved, or off-label use of drugs.Learners are advised to consult prescribing information for any products discussed. Theinformation provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support

.

Thanks for your interest in this podcast. Please read this important program information before listening. Access to the post-test and to claim credit for participating is included below.Activity OverviewThis PER® Spectives™ podcast features a discussion among 3 optometrists on concerns related to the use of preserved eye lubricants for patients with dry dye disease. In addition, the panel discusses developments in components within these products to support the ocular surface, including trehalose and hyaluronic acid. This program is designed to help clinicians better match specific eye lubrication products to individual patient needs, thereby improving the chances of superior outcomes.Accreditation/Credit DesignationPhysicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Acknowledgment of Educational Grant SupportThis activity is supported by an educational grant from Thea Pharmaceuticals, Inc.Target Audience  This educational activity will be targeted to clinicians who are involved in treating patients with dry eye disease such as optometrists, ophthalmologists, NPs, PAs, and nurses.Learning ObjectivesUpon successful completion of this activity, you should be better prepared to: • Recognize the potential deleterious impact preservatives have on the ocular surface• Summarize novel formulations for the management of DEDFaculty:Mile Brujic, OD, FAAOPartnerPremier Vision GroupBowling Green, OHDisclosures: Advisory/Research Support: ABB Optical, Alcon Laboratories, Allergan, Art Optical, Bausch +Lomb Health, Contamac, CooperVision, CSEye, Horizon Therapeutics, Johnson & Johnson Vision Care,Kala, Novartis, Optovue, Oyster Point, RVL, Sun Pharma, Tarsus, Tangible Science, Santen, WalmanOptical, ZeaVisionDavid Kading, OD, FAAO, FCLSACEO/OwnerSpecialty EyeKirkland, WA / Bellevue,WADisclosures:Alcon, Allergan, Avellino, Bausch + Lomb, BioTissue, CooperVision, EyeVance, Eye Promise Euclid, Horizon Lumenis, Oculus,Orasis, Oculaphire, Medmont, Novartis, Sun Pharma, TearScience, Thea, Trukara, Valley Contax, Visus Theraputics, Zeiss, andZeaVision.DisclosuresSelina R. McGee, OD, FAAOCEO/OwnerBeSpoke VisionPresidentIntrepid Eye SocietyOklahoma Board of Examiners in OptometryEdmond, OKDisclosures: Consultant: Horizon Therapeutics.The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with ineligible companies. PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.Off-Label Disclosure and DisclaimerThis activity may or may not discuss investigational, unapproved, or off-label use of drugs.Learners are advised to consult prescribing information for any products discussed. Theinformation provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient's medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial supportfor this activity.

A recent study compared GnRH antagonists in egg donor ovarian stimulation cycles. The first drug is a newer agent, elagolix (Orilissa), that is taken as a tablet at night. The older drug is an injectable agent called ganirelix (Fyremadel). How did Orilissa stack up in terms of eggs retrieved and embryos formed vs. ganirelix? Were there adverse events, like ovarian hyperstimulation or early LH surge? Results explored in this episode and what they mean for upcoming egg donor cycles. ResourcesBoniface C, Schnorr JN, Gray J, et al. The role of elagolix in the suppression of ovulation in donor oocyte cycles. F S Rep. 2023;4(2):179-182. Published 2023 Mar 25. doi:10.1016/j.xfre.2023.03.006Check JH, Brasile D, Choe JK, Amui J, Wilson C. The effect of cetrorelix vs. ganirelix on pregnancy outcome using minimal gonadotropin stimulation in women with elevated day 3 serum follicle stimulating hormone levels. Clin Exp Obstet Gynecol. 2009;36(3):148-149.Fyremadel [package insert]. Parsippany, NJ: Ferring Pharmaceuticals, Inc.; 2022. manufactured by Sun Pharma (India)Kay, C. Contaminated Drugs, Shredded Papers: US FDA Uncovers Failures in India Pharma Factories. May 31, 2013. Accessed July 11, 2023. https://www.bloomberg.com/news/articles/2023-05-31/us-finds-contaminated-drugs-further-lapses-in-india-pharma-factories-post-covid#xj4y7vzkgKeenan, J. Sun Pharma pauses US drug exports from India plant after FDA scolding. April 27, 2023. Accessed July 10, 2023. https://www.fiercepharma.com/manufacturing/sun-pharma-hits-pause-mohali-plant-response-fda-letter/Orilissa [package insert]. North Chicago, IL: Abbvie; 2021.Zhang J, Zhou X, Chen Y, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2019;39(10):1207-1212. doi:10.12122/j.issn.1673-4254.2019.10.12

.

Treatment options backed by real-world evidence means more opportunities for those living with moderate-to-severe plaque psoriasis. Join Steve Rozzo, Ph.D., Sun Pharma, and Neal Bhatia, M.D., Therapeutics Clinical Research in San Diego, CA in a Q&A discussion on real-world clinical data of ILUMYA® and what the findings mean for moderate-to-severe plaque psoriasis patients. Episode sponsored by Sun Pharma. Important safety information: https://bit.ly/2We7fIS .

Equities fought volatility and surged last week, as stocks danced to the tunes of global cues, domestic news flow and corporate earnings.  Among indices, financials lead from the front, while a steep cut in excise duty on fuel prices and capping of sugar exports, saw stocks from these sectors react negatively. Eventually, the BSE Sensex moved in a band of 1,500 points, and finally ended the week with 1 per cent gain. The NSE Nifty, on the other hand, was up 0.5 per cent, while the Bank Nifty surged nearly 4 per cent. However, despite last week's gains, the benchmark indices may end the current month on a negative note, marking their biggest declines in May since 2012. The BSE benchmark Sensex and the Nifty were down close to 4 per cent so far this month, primarily dragged down by the persistent FII selling.  Foreign investors have, now, been net sellers for eight straight months and have net sold stocks worth more than 52,000 crore rupees so far this month. According to VK Vijayakumar of Geojit Financial Services, FPI selling is showing mild signs of exhaustion. DII and retail buying together with overwhelming FPI selling along with short covering can trigger a near-term rally. High quality large-caps can stage a rally, says Vijayakumar, adding that leading banks are safe bets.  Against this backdrop, Business Standard's Avdhut Bagkar shares how the banking stock is placed on the charts. Going ahead, markets will look at Q1CY22 GDP number, slated to be announced on Tuesday, for fresh cues on the economic recovery. As per a Reuters poll of economists, India's economic recovery from the Covid-19 pandemic likely stumbled again in the first quarter of this year primarily due to Omicron-related restrictions and higher inflation. ‘Growth in Asia's third-largest economy was pencilled in at 4.0% for the January-March quarter from the same period a year ago, down from 5.4% in Q4 2021. If realised, that would be the slowest in a year and a third consecutive quarter of weaker growth'. Amid these triggers, technical charts suggest that the NSE Nifty managed to close above its 20-DMA for the first time since April 13, 2022. The Nifty may look to target the trendline resistance around 16,750 in the near term.  On the downside, the index can expect support around 16,200-level. As we draw curtains on the Q4 earnings season, stocks like Aurobindo Pharma, Delhivery, IRCTC, Jindal Steel and Sun Pharma could see some action ahead of earnings on Monday.

Equities fought volatility and surged last week, as stocks danced to the tunes of global cues, domestic news flow and corporate earnings.  Among indices, financials lead from the front, while a steep cut in excise duty on fuel prices and capping of sugar exports, saw stocks from these sectors react negatively. Eventually, the BSE Sensex moved in a band of 1,500 points, and finally ended the week with 1 per cent gain. The NSE Nifty, on the other hand, was up 0.5 per cent, while the Bank Nifty surged nearly 4 per cent. However, despite last week's gains, the benchmark indices may end the current month on a negative note, marking their biggest declines in May since 2012. The BSE benchmark Sensex and the Nifty were down close to 4 per cent so far this month, primarily dragged down by the persistent FII selling.  Foreign investors have, now, been net sellers for eight straight months and have net sold stocks worth more than 52,000 crore rupees so far this month. According to VK Vijayakumar of Geojit Financial Services, FPI selling is showing mild signs of exhaustion. DII and retail buying together with overwhelming FPI selling along with short covering can trigger a near-term rally. High quality large-caps can stage a rally, says Vijayakumar, adding that leading banks are safe bets.  Against this backdrop, Business Standard's Avdhut Bagkar shares how the banking stock is placed on the charts. Going ahead, markets will look at Q1CY22 GDP number, slated to be announced on Tuesday, for fresh cues on the economic recovery. As per a Reuters poll of economists, India's economic recovery from the Covid-19 pandemic likely stumbled again in the first quarter of this year primarily due to Omicron-related restrictions and higher inflation. ‘Growth in Asia's third-largest economy was pencilled in at 4.0% for the January-March quarter from the same period a year ago, down from 5.4% in Q4 2021. If realised, that would be the slowest in a year and a third consecutive quarter of weaker growth'. Amid these triggers, technical charts suggest that the NSE Nifty managed to close above its 20-DMA for the first time since April 13, 2022. The Nifty may look to target the trendline resistance around 16,750 in the near term.  On the downside, the index can expect support around 16,200-level. As we draw curtains on the Q4 earnings season, stocks like Aurobindo Pharma, Delhivery, IRCTC, Jindal Steel and Sun Pharma could see some action ahead of earnings on Monday.

After a hiatus of two years, the US Food and Drug Administration resumed its onsite inspections of drug manufacturing units outside its borders – including China and India. It has been following this practice to make sure that all the medicines which enter into the country follow the set standards. Most inspections were put on hold in March 2020, when the world was hit by the pandemic. Indian pharmaceutical companies, on their part, try to adhere to the norms as any departure may hit their export adversely. In one such inspection at Sun Pharma's Halol facility this month, the US FDA team issued a Form 483. The next morning of May 10, the share price of Sun Pharmaceutical Industries fell over four per cent. So, apparently, the Form 483 and 10 observations made in it were not good news for the firm. The company said that it was preparing a response to the observations, which would be submitted to the USFDA within 15 business days. The Food and Drug Administration has the responsibility of protecting public health in the US. In its own words, on the one hand, it does this by ensuring the safety, efficacy, and security of both human and veterinary drugs, biological products, and medical devices. On the other hand, the FDA is responsible for ensuring the safety of the US' food supply. It also deals with cosmetics and products that emit radiation.   According to the USFDA, an FDA Form 483 is issued to the management of the firm being inspected. It is issued at the end of the inspection if the FDA's investigators find that they have observed any conditions that might constitute violations of the Food Drug and Cosmetic Act and related Acts of the US. Observations are made when the investigators find that the conditions or practices observed indicate that any food items, drugs, devices or cosmetics have been adulterated. Or, if in their judgement, these products are being prepared, packed, or held under conditions in which they might become adulterated or rendered injurious to health.   On their part, the company that has been inspected is supposed to respond to the Form 483 in writing, along with its corrective action plan. The FDA expects that subsequently, the company will implement said plan expeditiously.

Indian equity markets have been at the mercy of foreign portfolio investors for over six months now. Since October 2021, FPIs have sold equities worth nearly 1.58 trillion rupees as rising crude oil prices and steep valuation of the markets made them nervous. Of this, peak selling was witnessed in March 2022, when FPIs sold equities worth 41,123 crore rupees. According to analysts at Jefferies India's positioning has come down to neutral or slight overweight level over the last 3-6 months, implying 50-100 bps weight reduction. While valuations have come off from peak, they still remain the key discomfort. VK Vijayakumar of Geojit Financial Services, says that along with relative rich valuations, FPIs think markets have not priced in Fed's monetary tightening.   That said, a recent trend has emerged in the markets, which is slowdown in the buying momentum of domestic institutional and retail investors. Data compiled by BS Research Bureau shows that DIIs bought equities worth 4,471 crore rupees in October last year. This buying increased to little over 42,000 crore rupees in February this year. However, so far in April, DIIs have bought equities worth 11,000 crore rupees only. So, is this a worrying sign for the markets? From investment viewpoint, analysts at HSBC remain bullish on defensiveness, recovery plays with strong earnings outlook, and industrials. Individually, they like ICICI Bank, Infosys, Bajaj Auto, Maruti, L&T, HUL, Apollo Hospitals and Sun Pharma. On Thursday, the BSE Sensex index ended at 57,912, up 874 points, while the Nifty50 closed at 17,393, up 256 points. On Friday, markets will react to HCL Tech's Q4 numbers and await March quarter earnings of Hindustan Zinc, Tata Metaliks and 12 other companies. Globally, developments around Ukraine-Russia war and rising Covid-19 cases will guide the sentiment.

# China Accused of cyber-attacks on Ukraine before Russian invasion# Buget 2022: $9.9 billion towards cyber security aims to make Australia a key 'offensive' cyber playerThese are some of the recent headlines around Cyber threats globally. Cyber attacks have been rated the fifth top rated risk in 2020 and continues to grow in 2022 as IoT cyber attacks alone are expected to double by 2025.In this episode our guest Rahul Sasi, Founder CloudSEK, talks about the key challenges in Cyber Security in India today.CloudSEK's customer list includes Axis Bank, NPCI, Netcore, OLA, Sun Pharma, ICICI Lombard, IndusInd Bank, MakeMyTrip and many more who don't wish to take a chance with the growing threat of global cyber crimes.  11 of the Fortune Global companies, and 7 of the world's biggest banks, trust XVigil (one of CloudSEK's flagship products) to safeguard their security posture.During the episode, Rahul talks about how they started CloudSEK, customer acquisition strategy, and much more.Notes - 04:04 - Background before starting CloudSEK08:55 - Current ARR and scale in terms of customers09:45 - Milestone since launch12:04 - Products and Problem Statements solved by CloudSEK14:44 - How has been the industry response? 20:19 - Challenges with hiring the right people24:40 - Targets for the next 2 years26:17 - Learnings from their fundraising journey28:26 - How to leverage your investors?

Top headlines   ·       Sensex slips 143 pts; Nifty holds 17,500; Realty worst hit ·       Nifty Metal shines; Hindustan Copper gains 6% ·       Godrej Properties slumps 10% as board approves stake buy in DB Realty ·       Monte Carlo Fashions sheds 10% on weak Q3 results ·       Vedant Fashions IPO subscribed only 11% on day 1   Mixed global cues kept the domestic equities volatile throughout the day on Friday, as Brent crude inched closer to $93-a-barrel mark, and bond yields climbed in the US and India, adding to the nervousness in the markets.   The BSE Sensex oscillated 517 points intra-day and eventually settled 143 points lower at 58,645. The Nifty50, on the other hand, ended at 17,516, down 44 points. Both benchmarks were down 0.2% each.   In the Sensex pack, SBI was the biggest loser. It dropped over 2%. M&M, NTPC, Kotak Bank, Bajaj Finserv, HDFC, Power Grid, and RIL were the other major losers.   On the upside, Sun Pharma, Asian Paints, Tata Steel, UltraTech Cement, and Bajaj Finance were the major gainers, all rising up to 1.4%.   The broader markets underperformed the benchmarks, with the BSE MidCap and SmallCap indices closing 0.7% and 0.45% lower, respectively.   Elsewhere in Asia, markets ended higher, with Japan's Nikkei and South Korea's Kospi rising 0.7% and 1.6%, respectively. European markets, however, were little changed. This was after the European Central Bank kept interest rates unchanged on Thursday, despite record inflation levels across the euro zone. The Bank of England, however, increased rates, in a first back-to-back rise since 2004.   Back home, among sectors, the Nifty Realty index was the biggest loser today. It closed 3% lower, and was followed by Nifty PSU Bank and Nifty Auto indices, which shed 2% and 1%, respectively. The Nifty IT and FMCG indices ended flat.   On the other hand, the Nifty Metal index was the sole gainer. It ended 1% higher in a weak market. Metal stocks have been gaining after the Union Budget proposed to extend customs duty exemption on steel scraps for a year. Index constituents Hindustan Copper, Vedanta, Ratnamani Metals, Hindustan Zinc and Jindal Steel were the top gainers, all up between 1% and 6%.   Among stocks, Monte Carlo Fashions lost 10% after investors were disappointed with its December quarter performance. The apparel company's net profit declined 2.4% year-on-year to Rs 77.45 crore. Its EBITDA margins also came lower at 24.6%, against 28.8% in the year-ago period.   Further, Godrej Properties slumped nearly 10% after its board approved an investment of Rs 400 crore in DB Realty to acquire around a 10% stake. The stock has tanked 16% in the past two sessions. The company also reported a subdued performance in the December quarter as its pre-sales volumes declined 7% year-on-year and 39% sequentially.   Lastly, the IPO of Manyavar owner Vedant Fashions saw a tepid response from investors on day 1 of the subscription period. As of 3:50 pm, the IPO had been subscribed only 11%, with the retail investor portion being subscribed 20%. The Non-Institutional Investor and Qualified Institutional Buyer categories did not see much participation.

Top headlines   ·       Bulls cheer Budget 2022; Sensex ends 848 pts higher, Nifty above 17,550 ·       Nifty Metal index soars 4%; Tata Steel, SAIL rally up to 7% ·       ITC jumps to 7-week high as no tobacco tax relieves investors ·       Sun Pharma rallies 7%, hits new 52-week high post Q3 results ·       Govt brings crypto currency, other digital assets under tax net   Frontline indices whipsawed in trade on Tuesday but eventually ended 1.4 per cent higher as investors gave a thumbs-up to the pro-growth Budget for 2022-23. Finance Minister Nirmala Sitharaman on Tuesday unveiled a Budget that aims to boost growth amid continued disruption from Covid-19 and rising inflation.   Moreover, analysts said the Budget continued the focus on quality expenditure. And, the capex increase of 35 per cent – in key sectors like Infra, housing, defence, railways and agriculture – could have a multiplier effect on the economy.   According to Vinod Nair, Head of Research at Geojit Financial Services, this Budget is expected to support growth in the long term, but high capex, fiscal deficit and borrowing plans against the backdrop of rising inflation, oil prices and interest rates could be some challenges in the short to medium term.   Equity markets logged strong gains after taking a sharp dip mid-way but recovered soon after. The S&P BSE Sensex jumped over 1,000 points to hit its intra-day high level but eventually ended 848 points higher at 58,863. The Nifty50 followed a similar trajectory and rose 367 points intra-day before it closed at 17,577, up 237 points.   Tata Steel, Sun Pharma, IndusInd Bank, L&T, Ultratech Cement, ITC, Titan and HCL Tech were the top gainers, while M&M, Bharti Airtel, SBI, PowerGrid and NTPC were top laggards.    In the broader markets, the BSE MidCap and SmallCap indices ended 1 per cent and 0.9 per cent higher, respectively. The volatility index, India VIX, cooled off 9 per cent to end below the 20 mark.   Sectorally, the Nifty PSU Bank index ended in the red, down 0.6 per cent, as the Budget document remained silent on PSB privatisation. The Nifty Auto index and the Oil & Gas index were other losers, closing 0.7 per cent down each.   On the upside, the Nifty Metal index zoomed nearly 5 per cent after the government announced its Rs 7.5-trillion capex plan for 2022-23. It also proposed to extend the customs duty exemption on steel scrap by one year.   Among individual stocks, FMCG major ITC closed 3% higher and hit a seven-week high on the BSE as the rumoured hike in taxes on tobacco was not proposed in the Budget.   Further, Sun Pharma ended nearly 7% higher on the BSE, as it hit a new 52-week high on reporting a good operational performance in the December quarter. The drug maker's revenue and PAT grew 11 per cent year-on-year.   Lastly, one of the most attention-grabbing announcements from the Budget was the levy of tax on digital assets like cryptocurrency. The Finance Minister said that gifts received in the form of cryptocurrencies and other virtual digital assets would be taxed at 30 per cent in the hands of the receiver. This move is believed to have finally brought cryptocurrencies and NFTs under a legal tax net in the country.

Richard Mangan, OD, FAAO, is a 30-year industry clinician who now does medical liaison work for Sun Pharma, and is also on the editorial board of ModernOD.  As someone who has studied the research on physician burnout, Dr. Mangan gives insights on his experiences with burnout, as well as potential methods to deal with it.  As October winds down the recognition of Mental Health Awareness Month, this Sandbox Story looks to remind the eye care professions of the importance of self-care and emotional wellness.     Resources:  Dr. Mangan's recent article on burnout: https://modernod.com/articles/2021-july-aug/physician-burnout-and-its-implications?c4src=article:infinite-scroll. Suicide Prevention Lifeline:  800-273-8255 Suicide Prevention Lifeline Chat:  SuicidePreventionLifeline.org   The Stories within the Story include: 2:45  The Story of Interest in Burnout 3:42  The Story of Newfound Consideration 4:29  The Story of Defining Burnout 7:45  The Story of Indicators of Burnout 9:10  The Story of Reducing Burnout 11:00  The Story of Reducing Suicide Risk 13:02  The Story of Positive Life Adjustments   Runtime:  18 min

John Kane, Head of Commercial Training and Development at Sun Pharma. John shares his thoughts on leadership as a journey and why it's so important for leaders to put their self-interest aside and demonstrate a genuine interest in others.

What did you do when you were 25 years old? Listen to the fascinating story of M Yuvan, a young Naturalist | Writer | Educator | Activist and a gift to mankind. Ram and me learned so much from our conversation with Yuvan on nature, awareness of issues around us, parenting, teaching, British atrocities and many other things .... writing a description for this episode is like trying to put two arms around Mother Earth! there is only one way to understand it ... just listen! A must listen episode for every single parent and child ... You can get Yuvan's book here Please do use this fantastic resource on the coastal fauna of Chennai by Madras Naturalist Society @ https://tinyurl.com/chennaicoast Link to Chennai Climate Action Group @ https://chennaiclimateactiongroup.wordpress.com/ Follow Yuvan on Instagram @a_naturalists_column ... Twitter @Yuvan_aves Created by : Ram and Bharad Music Credits : The awesome folks at Ample Tunes